VivoSim Lab, Inc.（简称VivoSim）宣布，已收到来自全球制药巨头礼来公司的一笔500万美元里程碑付款。与此同时，公司发布了业绩指引，预计在2027财年将实现超过500%的营收增长。
这一里程碑付款的达成，标志着双方在特定合作项目上取得了关键进展。VivoSim并未披露具体的合作细节，但此类付款通常与药物研发过程中达到预设的临床或监管目标相关联。
公司对未来业绩的展望极为乐观。超过500%的营收增长预期，远超行业平均水平，显示出管理层对公司核心业务增长潜力和市场扩张能力的强大信心。这一指引可能基于现有合作项目的推进、新协议的签署以及市场需求的持续增长。
投资者将密切关注VivoSim后续的财务报告和业务进展，以验证这一雄心勃勃的增长目标。获得礼来这样的行业领导者的里程碑付款，不仅为公司带来了即时的现金流，也增强了其技术平台和研发能力的可信度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.